Phase II trial demonstrates effectiveness of rare sarcoma drug
An experimental drug has been found to aid the treatment of advanced alveolar soft part sarcoma
A phase II clinical trial has demonstrated that cediranib may be an effective experimental drug for the treatment of advanced alveolar soft part sarcoma (ASPAS).
Research, published in the Journal of Clinical Oncology, explained how 43 patients with metastatic ASPS were administered a daily 30 milligram oral dose of cediranib until they either developed significant side effects or the disease progressed.
The objective response rate was 35 per cent, which is related to a 30 per cent reduction in the size of the tumour being targeted.
Some 15 of patients achieved a partial response, while 60 per cent had stable disease, the US study revealed.
"It's unusual to see such high rates of tumour shrinkage in a cancer that traditionally has not responded to standard chemotherapy treatments used for sarcomas," said Dr Shivaani Kummar, principal investigator on the trial.
ASPS is believed to make up less than one per cent of soft tissue sarcomas, which are cancers that begin in connective and supportive tissue.
The most commonly recommended treatment for the disease is surgical removal of the tumours.
Related News
-
News A Day in the Life of a Start-Up Founder and CEO
At CPHI we work to support Start-Up companies in the pharmaceutical industry and recognise the expertise and innovative angles they bring to the field. Through our Start-Up Programme we have gotten to know some of these leaders, and in this Day in the ... -
News Biopharmaceutical manufacturing boost part of new UK government budget
In their national budget announced by the UK Labour Party, biopharmaceutical production and manufacturing are set to receive a significant boost in capital grants through the Life Sciences Innovative Manufacturing Fund (LSIMF). -
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance